(616 Kb) -

The study highlighted a few differences between "real-world" patients and those in trials:

The search for a "616 KB" article points directly to a significant medical study titled (616 KB)

The authors argue that because the drug is highly effective but often hard to tolerate, the medical community should focus on: The study highlighted a few differences between "real-world"

: For those who stopped the medication, the median time until they did so was only 7 months . (616 KB)

: Despite the high rate of stopping, the overall survival and progression-free survival (estimated at 35 months) remained excellent. Real-World vs. Clinical Trials

: A major finding was that 41% of patients stopped taking ibrutinib within a median of 17 months.